Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO

NCT04676737 is registered in ClinicalTrials.gov with Trefoil Therapeutics, Inc. as lead sponsor.

NCT NCT04676737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO
Lead sponsor
Trefoil Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2021
Completion date
January 13, 2023
Enrollment
49 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

fuchs, fuchs dystrophy, fuchs' endothelial dystrophy